Global Firms Dominate 60% of Indian Vaccine Sales

Global pharmaceutical companies lead the Indian vaccine market with a value share of 60%.

India's vaccine market is still recovering from the impact of COVID-19, and many nations have regained strength, according to data from research firm PharmaTrac.

Due to the high value of their products, the market share of multinationals is growing faster than national pharmaceutical companies, which are recording the pace of growth. British pharmaceutical company GlaxoSmithKline is a leader in the Indian vaccine market.MNCs have a value growth similar to that of Indian companies, albeit slower.

Although vaccines are becoming more popular at home, some remain the exclusive domain of many companies, say industry experts, who cite reasons for this trend. PfizerLand's Prevenar 13 (pneumococcal vaccine) had January sales of $61.3 billion, nearly three times the sales of its Indian rival, Serum Institute of India's (SII) pneumococcal vaccine ($21.2 billion). , will display the data.